Log In
Print this Print this

Anti-IL-21 (NN8828)

  Manage Alerts
Collapse Summary General Information
Company Novo Nordisk A/S
DescriptionRecombinant human mAb against IL-21
Molecular Target Interleukin-21 (IL-21)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today